腾盛博药-B(02137)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02137 腾盛博药-B

已收盘 12-19 16:08:47

0.860

+0.010

+1.18%

最高0.860	最低0.830	成交量30.95万
今开0.860	昨收0.850	日振幅3.53%
总市值6.29亿	流通市值6.29亿	总股本7.31亿
成交额26.19万	换手率0.04%	流通股本7.31亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02137","market":"HK","secType":"STK","nameCN":"腾盛博药-B","latestPrice":0.86,"timestamp":1734595727014,"preClose":0.85,"halted":0,"volume":309500,"delay":0,"floatShares":731000000,"shares":731000000,"eps":-0.25757736,"marketStatus":"已收盘","marketStatusCode":5,"change":0.01,"latestTime":"12-19 16:08:47","open":0.86,"high":0.86,"low":0.83,"amount":261890,"amplitude":0.035294,"askPrice":0.87,"askSize":14000,"bidPrice":0.85,"bidSize":34000,"shortable":0,"etf":0,"ttmEps":-0.3904895660409636,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734658200000},"adr":0,"listingDate":1626105600000,"adjPreClose":0.85,"openAndCloseTimeList":[[1734571800000,1734580800000],[1734584400000,1734595200000]],"volumeRatio":0.155208,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02137","defaultTab":"news","newsList":[{"id":"2492188353","title":"董事会主席兼执行董事洪志博士增持腾盛博药-B(02137)5万股 每股作价0.8976港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492188353","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492188353?lang=zh_cn&edition=full","pubTime":"2024-12-18 20:46","pubTimestamp":1734525966,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，12月13日，董事会主席兼执行董事洪志博士增持腾盛博药-B(02137)5万股，每股作价0.8976港元，总金额约为4.49万港元。增持后最新持股数目约为4129.78万股，最新持股比例为5.65%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226741.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02137","BK1574","BK1587","BK1161"],"gpt_icon":0},{"id":"2492707987","title":"腾盛博药-B12月17日遭主力抛售127万元 环比增加746.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492707987","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492707987?lang=zh_cn&edition=full","pubTime":"2024-12-17 16:16","pubTimestamp":1734423368,"startTime":"0","endTime":"0","summary":"12月17日, 腾盛博药-B股价跌6.82%，报收0.82元，成交金额359万元，换手率0.59%，振幅9.09%，量比3.29。腾盛博药-B今日主力资金净流出127万元，上一交易日主力净流出15万元，今日环比增加746.67%。该股近5个交易日下跌12.77%，主力资金累计净流出286万元；近20日主力资金累计净流出364万元，其中净流出天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217161644a1f542b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217161644a1f542b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","02137","BK1161","BK1574"],"gpt_icon":0},{"id":"2492598351","title":"腾盛博药-B(02137)下跌5.68%，报0.83元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492598351","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492598351?lang=zh_cn&edition=full","pubTime":"2024-12-17 14:05","pubTimestamp":1734415556,"startTime":"0","endTime":"0","summary":"12月17日，腾盛博药-B(02137)盘中下跌5.68%，截至14:05，报0.83元/股，成交180.12万元。腾盛博药生物科技有限公司主要业务是针对未被满足的病人需求和有限的治疗手段，开发针对感染性疾病和中枢神经系统疾病的创新疗法。该公司成立于2018年，现业务遍布罗利-达勒姆、旧金山湾区和中国的北京与上海，于2021年在香港交易所挂牌上市，股票代码为2137.HK。截至2023年年报，腾盛博药-B营业总收入61.7万元、净利润-1.75亿元。8月19日，腾盛博药-B披露2024财年中报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/17140546463771.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","BK1587","BK1161","02137"],"gpt_icon":0},{"id":"2492989899","title":"腾盛博药-B盘中异动 快速下挫5.68%报0.830港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492989899","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492989899?lang=zh_cn&edition=full","pubTime":"2024-12-17 14:05","pubTimestamp":1734415553,"startTime":"0","endTime":"0","summary":"2024年12月17日下午盘14时05分，腾盛博药-B股票出现异动，股价快速跳水5.68%。截至发稿，该股报0.830港元/股，成交量210.35万股，换手率0.29%，振幅5.68%。资金方面，该股资金流入30.2555万港元，流出146.693万港元。腾盛博药-B股票所在的生物技术行业中，整体涨幅为0.23%。腾盛博药-B公司简介：腾盛博药生物科技有限公司是一家主要专注于开发感染性疾病及中枢神经系统疾病治疗方案的生物技术公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217140553984c84e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217140553984c84e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","BK1161","02137","BK1574"],"gpt_icon":0},{"id":"2490004462","title":"“第九届智通财经资本市场年会暨上市公司颁奖典礼”26项大奖揭晓：245家公司分获殊荣!","url":"https://stock-news.laohu8.com/highlight/detail?id=2490004462","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490004462?lang=zh_cn&edition=full","pubTime":"2024-12-11 12:31","pubTimestamp":1733891515,"startTime":"0","endTime":"0","summary":"2024年12月11日上午，“第九届智通财经资本市场年会暨上市公司颁奖典礼” 在深圳隆重开幕。“第九届智通财经上市公司评选”自2016年启动以来，已连续成功举办9届。接近岁末，在全球资本的版图中，港股市场再度成为焦点。截至11月底，南向资金已连续17个月净流入，年内净买入总额突破7300亿港元，创下10年新高。剔除重复获奖，本届上市公司颁奖典礼共有245家公司及其高管分享这些荣誉。评选期间，吸引了超过1000家港美股上市公司积极参与。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223189.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01783","01598","02018","06122","01880","06633","01735","00826","02020","00291","01450","02100","01093","02171","00780","00799","00017","00855","01405","01117","00451","00268","01651","00798","01427","01471","02225","02137","02145","01378","00460","01121","09919","01083","02158","09896","06058","06677","01969","02105","06682","00003","01907","00552","01992","01519","02013","06680","06086"],"gpt_icon":0},{"id":"2490039067","title":"腾盛博药-B盘中异动 大幅拉升5.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490039067","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490039067?lang=zh_cn&edition=full","pubTime":"2024-12-10 09:30","pubTimestamp":1733794220,"startTime":"0","endTime":"0","summary":"2024年12月10日早盘09时30分，腾盛博药-B股票出现异动，股价急速拉升5.32%。腾盛博药-B股票所在的生物技术行业中，整体涨幅为0.75%。其相关个股中，药明巨诺-B、再鼎医药、药明合联涨幅较大，振幅较大的相关个股有康诺亚-B、腾盛博药-B、药明合联，振幅分别为4.65%、4.26%、3.15%。腾盛博药-B公司简介：腾盛博药生物科技有限公司是一家主要专注于开发感染性疾病及中枢神经系统疾病治疗方案的生物技术公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210093020984ae02f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210093020984ae02f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","BK1161","02137","BK1574"],"gpt_icon":0},{"id":"2489429038","title":"腾盛博药－Ｂ(02137)股价上升5.376%，现价港币$0.98","url":"https://stock-news.laohu8.com/highlight/detail?id=2489429038","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489429038?lang=zh_cn&edition=full","pubTime":"2024-12-06 11:25","pubTimestamp":1733455500,"startTime":"0","endTime":"0","summary":"[上升股]腾盛博药－Ｂ(02137) 股价在上午11:25比前收市价上升5.376%，现股价为港币$0.98。至目前为止，今日最高价为$0.98，而最低价为$0.91。总成交量为62.75万股，总成交金额为港币$58.077万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190515141040914_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190515141040914_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2412062670/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02137","BK1587","BK1574","BK1161"],"gpt_icon":0},{"id":"2486507851","title":"董事会主席兼首席执行官Hong Zhi增持腾盛博药-B(02137)2.05万股 每股作价约1港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486507851","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486507851?lang=zh_cn&edition=full","pubTime":"2024-11-26 18:02","pubTimestamp":1732615320,"startTime":"0","endTime":"0","summary":"香港联交所最新资料显示，11月25日，董事会主席兼首席执行官Hong Zhi增持腾盛博药-B(02137)2.05万股，每股作价1.0007港元，总金额约为2.05万港元。增持后最新持股数目约为4107.48万股，最新持股比例为5.62%。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-26/doc-incxkxsk4155731.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1587","BK1161","02137","BK1574"],"gpt_icon":0},{"id":"2486309740","title":"腾盛博药－Ｂ(02137)股价上升5%，现价港币$1.05","url":"https://stock-news.laohu8.com/highlight/detail?id=2486309740","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486309740?lang=zh_cn&edition=full","pubTime":"2024-11-25 10:29","pubTimestamp":1732501740,"startTime":"0","endTime":"0","summary":"[上升股]腾盛博药－Ｂ(02137) 股价在上午10:29比前收市价上升5%，现股价为港币$1.05。至目前为止，今日最高价为$1.05，而最低价为$0.98。总成交量为17.6万股，总成交金额为港币$17.619万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR241125877/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1587","02137","BK1161","BK1574"],"gpt_icon":0},{"id":"2485257778","title":"美国乙肝疫苗公司破产，绊倒中国创新药企","url":"https://stock-news.laohu8.com/highlight/detail?id=2485257778","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485257778?lang=zh_cn&edition=full","pubTime":"2024-11-22 20:47","pubTimestamp":1732279635,"startTime":"0","endTime":"0","summary":"11月15日，VBI Vaccines宣布：公司破产终止运营，将在全美范围内召回乙肝 疫苗 PreHevbrio。11月19日，腾盛博药回应健识局称：撤回是因对方公司破产和运营终止，而非产品问题。双方捆绑颇深PreHevbrio是美国市场上获批的唯一一款靶向3种乙肝病毒抗原的预防性成人乙肝疫苗，已经在美国、英国、加拿大、欧盟等地区上市。腾盛博药可能并不是特别看重乙肝疫苗PreHevbrio。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122210054a24df930&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122210054a24df930&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","BK1574","02137","BK1161","BK1587"],"gpt_icon":0},{"id":"2484917402","title":"腾盛博药-B(02137)：以最新突破口头报告的形式公布了正在进行的2期ENSURE研究的最新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2484917402","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484917402?lang=zh_cn&edition=full","pubTime":"2024-11-19 19:47","pubTimestamp":1732016840,"startTime":"0","endTime":"0","summary":"智通财经APP讯，腾盛博药-B 发布公告，在11月15日至19日于美国加利福尼亚州圣地亚哥举行的美国肝病研究学会年会上，公司以最新突破口头报告的形式公布了其正在进行的2期ENSURE研究的最新数据。我们将在2025年的科学会议上分享关键数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213064.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","02137","BK1587"],"gpt_icon":0},{"id":"2484468989","title":"腾盛博药首次在2024年美国肝病研究学会 (AASLD) 年会上发布siRNA (Elebsiran) 联合PEG-IFNα 对比PEG-IFNα 单药治疗的结果，证明联合siRNA可更显著提高HBV表面抗原清除","url":"https://stock-news.laohu8.com/highlight/detail?id=2484468989","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484468989?lang=zh_cn&edition=full","pubTime":"2024-11-19 19:30","pubTimestamp":1732015800,"startTime":"0","endTime":"0","summary":"既往研究显示，siRNA联合PEG-IFNα是最有希望获得更高HBsAg血清清除的疗法之一。ENSURE研究首次为siRNA在已有的PEG-IFNα疗法基础上对实现功能性治愈的作用提供了证据。我们相信，elebsiran有望对提高HBV功能性治愈率产生重要影响。该结果凸显了elebsiran作为目前正在开展的多项临床研究中进行评估的联合治疗方案核心的潜力。在病毒学抑制的慢性HBV感染参与者中，elebsiran联合PEG-IFNα治疗总体安全且耐受性良好。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4560618_ZH60618_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4585","BK1587","IE00BMG7P694.USD","IE00BMG7P819.SGD","BK1574","IE00BD4GTW91.USD","IE00BD4GTV84.USD","02137","IE00BD4GTT62.SGD","IFN","BK4523","IE00BMG7P587.USD","BK1161","PEG","BK4588","BK4208","IE00BMG7P926.USD"],"gpt_icon":1},{"id":"1130441373","title":"异动解读 | 腾盛博药-B股价盘中暴跌7.41%,业绩下滑及机构评级持有或是主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1130441373","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130441373?lang=zh_cn&edition=full","pubTime":"2024-11-19 10:36","pubTimestamp":1731983811,"startTime":"0","endTime":"0","summary":"腾盛博药-B(02137)今日盘中股价暴跌7.41%,引发市场高度关注。\n\n资料显示,该公司最新财报数据不佳,净利润录得-3.07亿港元,每股亏损0.42港元。另外,虽然1家参与评级的机构100%给予持有评级,但缺乏买入评级,或令投资者对公司前景信心不足。\n\n虽然公司在传染病及中枢神经系统疾病治疗领域仍有一定增长潜力,但短期面临业绩下滑及机构评级不利的双重压力,或是导致其股价暴跌的主因。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 腾盛博药-B股价盘中暴跌7.41%,业绩下滑及机构评级持有或是主因","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02137"],"gpt_icon":0},{"id":"2484959432","title":"腾盛博药-B(02137)下跌7.41%，报1.0元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484959432","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484959432?lang=zh_cn&edition=full","pubTime":"2024-11-19 10:23","pubTimestamp":1731983019,"startTime":"0","endTime":"0","summary":"11月19日，腾盛博药-B(02137)盘中下跌7.41%，截至10:23，报1.0元/股，成交171.96万元。腾盛博药生物科技有限公司主要业务是针对未被满足的病人需求和有限的治疗手段，开发针对感染性疾病和中枢神经系统疾病的创新疗法。该公司成立于2018年，现业务遍布罗利-达勒姆、旧金山湾区和中国的北京与上海，于2021年在香港交易所挂牌上市，股票代码为2137.HK。截至2023年年报，腾盛博药-B营业总收入61.7万元、净利润-1.75亿元。8月19日，腾盛博药-B披露2024财年中报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/19102345437889.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","BK1574","BK1587","02137"],"gpt_icon":0},{"id":"2484955756","title":"腾盛博药-B盘中异动 早盘股价大跌7.41%报1.000港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484955756","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484955756?lang=zh_cn&edition=full","pubTime":"2024-11-19 10:14","pubTimestamp":1731982456,"startTime":"0","endTime":"0","summary":"2024年11月19日早盘10时14分，腾盛博药-B股票出现异动，股价急速下挫7.41%。截至发稿，该股报1.000港元/股，成交量80.45万股，换手率0.11%，振幅7.41%。资金方面，该股资金流入21.6万港元，流出61.8595万港元。机构评级方面，在所有1家参与评级的机构中，100%的券商给予持有建议，无券商给予买入、卖出建议。腾盛博药-B股票所在的生物技术行业中，整体涨幅为0.31%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119101416abcde9c6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119101416abcde9c6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02137","BK1161","BK1587","BK1574"],"gpt_icon":0},{"id":"2484273956","title":"腾盛博药－Ｂ(02137)股价下跌5.556%，现价港币$1.02","url":"https://stock-news.laohu8.com/highlight/detail?id=2484273956","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484273956?lang=zh_cn&edition=full","pubTime":"2024-11-19 10:14","pubTimestamp":1731982440,"startTime":"0","endTime":"0","summary":"[下跌股]腾盛博药－Ｂ(02137) 股价在上午10:14比前收市价下跌5.556%，现股价为港币$1.02。至目前为止，今日最高价为$1.08，而最低价为$1.02。总成交量为43.85万股，总成交金额为港币$45.982万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152742524_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152742524_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD241119360/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","02137","BK1587","BK1161"],"gpt_icon":0},{"id":"2483331937","title":"好样的！见义勇为的市场监管干部洪志鑫","url":"https://stock-news.laohu8.com/highlight/detail?id=2483331937","media":"中国质量新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483331937?lang=zh_cn&edition=full","pubTime":"2024-11-15 14:41","pubTimestamp":1731652860,"startTime":"0","endTime":"0","summary":"泉州市食药认证监测中心的洪志鑫作为“见义勇为先进群体”代表参会并发言，鲤城区区长王克思为其颁发荣誉证书。提起洪志鑫见义勇为的事迹，还得从今年10月5日说起。洪志鑫松了一口气，跟司机沟通女乘客的病情，建议继续前往医院就诊。受救女乘客携家属给洪志鑫赠送锦旗。洪志鑫同志用自己的实际行动在危急时刻挽救他人生命，诠释了见义勇为的传统美德，充分体现了市场监管人员的优秀品质。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-11-15/doc-incwcqvn3434495.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","02137","BK1587","BK1161"],"gpt_icon":0},{"id":"2483398810","title":"腾盛博药-B(02137)下跌6.78%，报1.1元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483398810","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483398810?lang=zh_cn&edition=full","pubTime":"2024-11-14 14:40","pubTimestamp":1731566402,"startTime":"0","endTime":"0","summary":"11月14日，腾盛博药-B(02137)盘中下跌6.78%，截至14:40，报1.1元/股，成交107.3万元。腾盛博药生物科技有限公司主要业务是针对未被满足的病人需求和有限的治疗手段，开发针对感染性疾病和中枢神经系统疾病的创新疗法。该公司成立于2018年，现业务遍布罗利-达勒姆、旧金山湾区和中国的北京与上海，于2021年在香港交易所挂牌上市，股票代码为2137.HK。截至2023年年报，腾盛博药-B营业总收入61.7万元、净利润-1.75亿元。8月19日，腾盛博药-B披露2024财年中报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/14144045283806.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02137","BK1587","BK1574","BK1161"],"gpt_icon":0},{"id":"2483938888","title":"腾盛博药-B盘中异动 急速拉升6.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483938888","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483938888?lang=zh_cn&edition=full","pubTime":"2024-11-14 09:44","pubTimestamp":1731548642,"startTime":"0","endTime":"0","summary":"2024年11月14日早盘09时44分，腾盛博药-B股票出现异动，股价急速上涨6.78%。截至发稿，该股报1.260港元/股，成交量15万股，换手率0.02%，振幅6.78%。腾盛博药-B股票所在的生物技术行业中，整体跌幅为0.27%。腾盛博药-B公司简介：腾盛博药生物科技有限公司是一家总部位于中国和美国主要从事传染病疗法研发业务的生物技术公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111409440298e42838&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111409440298e42838&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02137","BK1161","BK1587","BK1574"],"gpt_icon":0},{"id":"2483013077","title":"腾盛博药-B(02137)上涨9.26%，报1.18元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483013077","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483013077?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:25","pubTimestamp":1731464707,"startTime":"0","endTime":"0","summary":"11月13日，腾盛博药-B(02137)盘中上涨9.26%，截至10:25，报1.18元/股，成交157.91万元。腾盛博药生物科技有限公司主要业务是针对未被满足的病人需求和有限的治疗手段，开发针对感染性疾病和中枢神经系统疾病的创新疗法。该公司成立于2018年，现业务遍布罗利-达勒姆、旧金山湾区和中国的北京与上海，于2021年在香港交易所挂牌上市，股票代码为2137.HK。截至2023年年报，腾盛博药-B营业总收入61.7万元、净利润-1.75亿元。8月19日，腾盛博药-B披露2024财年中报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/13102545231708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","02137","BK1161","BK1587"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.briibio.com","stockEarnings":[{"period":"1week","weight":-0.086},{"period":"1month","weight":-0.213},{"period":"3month","weight":-0.086},{"period":"6month","weight":-0.2202},{"period":"1year","weight":-0.6101},{"period":"ytd","weight":-0.6272}],"compareEarnings":[{"period":"1week","weight":-0.0144},{"period":"1month","weight":0.0147},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.1018},{"period":"1year","weight":0.2035},{"period":"ytd","weight":0.1653}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"腾盛博药生物科技有限公司是一家总部位于中国和美国主要从事传染病疗法研发业务的生物技术公司。该公司的产品应用于传染病（如乙型肝炎病毒(HBV)、人类免疫缺陷病毒(HIV)、多重耐药(MDR)或广泛耐药性(XDR)革兰氏阴性菌感染）及其他具有重大公共卫生负担的疾病（如中枢神经系统(CNS)疾病）。该公司还开发用于COVID-19等的疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.139084},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.166803},{"month":3,"riseRate":0,"avgChangeRate":-0.321072},{"month":4,"riseRate":0.333333,"avgChangeRate":0.044149},{"month":5,"riseRate":0,"avgChangeRate":-0.067206},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.097476},{"month":7,"riseRate":1,"avgChangeRate":0.066427},{"month":8,"riseRate":0.25,"avgChangeRate":0.023974},{"month":9,"riseRate":0.5,"avgChangeRate":-0.020754},{"month":10,"riseRate":0.25,"avgChangeRate":-0.137315},{"month":11,"riseRate":0.75,"avgChangeRate":0.36887},{"month":12,"riseRate":0,"avgChangeRate":-0.179081}],"exchange":"SEHK","name":"腾盛博药-B","nameEN":"BRII-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"腾盛博药-B(02137)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供腾盛博药-B(02137)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"腾盛博药-B,02137,腾盛博药-B股票,腾盛博药-B股票老虎,腾盛博药-B股票老虎国际,腾盛博药-B行情,腾盛博药-B股票行情,腾盛博药-B股价,腾盛博药-B股市,腾盛博药-B股票价格,腾盛博药-B股票交易,腾盛博药-B股票购买,腾盛博药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"腾盛博药-B(02137)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供腾盛博药-B(02137)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}